Research programme: gram-negative infection therapeutics - Auransa
Latest Information Update: 28 Jun 2023
Price :
$50 *
At a glance
- Originator Auransa
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Gram-negative-infections in USA
- 27 May 2019 Early research in Gram-negative infections in USA (unspecified route) before May 2019 (Auransa pipeline, May 2019)
- 27 May 2019 Auransa announces intention to submit IND application to the US FDA (Auransa pipeline, May 2019)